Home › Prostate Cancer › NCT06610825
Castrate Resistant Prostate Cancer Enhertu Therapy
RecruitingPhase 2
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fam-Trastuzumab Deruxtecan-Nxki (T-DXd) as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma
Who can join
Ages 18 and older · Men
Full eligibility criteria
Inclusion Criteria: * Pathologically confirmed adenocarcinoma of the prostate * Diagnosis of mCRPC * Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen * Ongoing ADT to maintain serum testosterone levels below 50 ng/dL * Formalin fixed paraffin embedded tumor tissue for HER2 immunohistochemistry * Life expectancy 6 months * ECOG 0 or 1 * LVEF at least 50% * Adequate Blood Clotting function * Adequate Organ and Bone Marrow function * Adequate Renal function * Adequate Hepatic function Exclusion Criteria: * History of interstitial lung disease or pneumonitis requiring steroids * Significant coronary vascular disease * Previous exposure to HER2 targeted therapy
About the study
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
What is being tested
- Enhertu (drug)
Sponsor: Washington D.C. Veterans Affairs Medical Center · Participants: 60 · Started: Mar 5, 2025
Contact the study team
- Asha Escobar · Phone: 2027431090
Official record on ClinicalTrials.gov — NCT06610825
Locations in the U.S.
| District of Columbia | Washington DC VAMC, Washington D.C. |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.